Fig.6

Relative Responsiveness of QLU-C10D and EQ-5D-3L to Changes in Treatment Arms, Adverse Event (AE) Groups, and Response Groups from Baseline to End Of Treatment across Four Lux-Lung Trials (LL1, LL3, LL5, LL8), Using Six Country-Specific Value Sets (Australia, Canada, Italy, the Netherlands, Poland, and the United Kingdom). “b” = between groups; “w” = within groups; (A & C) Horizontal graphs represent range of RE values with six country value set pairs (QLU-C10D & EQ-5D-3L). Icons at each endpoint of the graphs signify country value set pairs with lowest and highest RE value. RE > 1 favors QLU-C10D, RE < 1 favors EQ-5D-3L. (B & D) Horizontal graphs represent range of differences between ES (between groups = Cohen’s d; within groups = DRI) calculated with each of the six country value set pairs of the two measures. Icons at the endpoints of the graphs signify country value sets with the smallest and largest distances from 0 (= no difference in ES). ES-Differences > 0 favor QLU-C10D, ES-Differences < 0 favor EQ-5D-3L. Abbreviations: AE  adverse events; DRI  difference responsiveness index, ES effect size; LL#   lux-lung trial number, RE  relative efficiency, AUS Australia, CAN  Canada, ITA   Italy, NLD the Netherlands, POL  Poland, UK  the United Kingdom.